Federico Nichetti, Simone Rota, Paolo Ambrosini, Chiara Pircher, Eleonora Gusmaroli, Michele Droz Dit Busset, Sara Pusceddu, Carlo Sposito, Jorgelina Coppa, Federica Morano, Filippo Pietrantonio, Maria Di Bartolomeo, Luigi Mariani, Vincenzo Mazzaferro, Filippo de Braud, Monica Niger
IMPORTANCE: The NAPOLI 3 trial showed the superiority of fluorouracil, leucovorin, liposomal irinotecan, and oxaliplatin (NALIRIFOX) over the combination of gemcitabine and nab-paclitaxel (GEM-NABP) as first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). Analyses comparing NALIRIFOX and GEM-NABP with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) have not yet been reported. OBJECTIVE: To derive survival, response, and toxic effects data from phase 3 clinical trials and compare NALIRIFOX, FOLFIRINOX, and GEM-NABP...
January 2, 2024: JAMA Network Open